Before matching, compared with non-SGLT-2 inhibitors, patients newly prescribed an SGLT-2 inhibitor therapy at baseline were younger and less frequently had a history of ischemic stroke or chronic kidney disease. This evidence concerns the gene SLC5A2 and chronic kidney disease.